Ross Moat Sells 23,234 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) insider Ross Moat sold 23,234 shares of the firm’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $28.02, for a total value of $651,016.68. Following the transaction, the insider now directly owns 9,415 shares in the company, valued at $263,808.30. This trade represents a 71.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ross Moat also recently made the following trade(s):

• On Tuesday, April 29th, Ross Moat sold 64,035 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $25.21, for a total value of $1,614,322.35.
• On Monday, April 21st, Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.29, for a total value of $370,475.11.

Kiniksa Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ KNSA opened at $27.65 on Friday. The firm has a fifty day simple moving average of $21.77 and a two-hundred day simple moving average of $21.36. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $17.38 and a 12 month high of $28.15. The firm has a market capitalization of $2.01 billion, a PE ratio of -197.49 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same period last year, the business posted ($0.25) earnings per share. Kiniksa Pharmaceuticals’s quarterly revenue was up 72.5% compared to the same quarter last year. On average, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after buying an additional 568 shares in the last quarter. Asset Management One Co. Ltd. bought a new stake in Kiniksa Pharmaceuticals during the first quarter worth about $41,000. Wealthquest Corp purchased a new stake in Kiniksa Pharmaceuticals in the first quarter worth about $42,000. Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $61,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $158,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of recent analyst reports. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $38.00.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.